With a market cap of around $730 billion, Eli Lilly (NYSE: LLY) is one of the largest pharmaceutical companies on planet ...

Wall Street expects good news when Lilly announces its Q3 results on Oct. 30. Lilly's stock might not perform as you think it ...

Eli Lilly has agreed to acquire eye disease specialist Adverum Biotechnologies, bucking a recent trend of big pharma ...

An experimental GLP-1/glucagon (GCP) dual receptor agonist from Eli Lilly and its Chinese partner Innovent has bested Novo Nordisk’s reigning GLP-1 semaglutide in a phase 3 study across both b | ...

Indianapolis: Eli Lilly and Company has announced that the U.S. Food and Drug Administration (FDA) has approved a ...

Two Texas compounding pharmacies are the latest to get sued in Eli Lilly’s multi-state battle to stop sales of replica ...

Eli Lilly and Company (NYSE:LLY) is one of the stocks in focus in the game plan Jim Cramer shared. Cramer noted that the ...

See, LLY stock warrants your attention. Why? Because it offers monopoly-like high margins at a discounted price.

Eli Lilly has reported that its interleukin-13 (IL-13) inhibitor Ebglyss (lebrikizumab-lbkz) showed sustained skin clearance ...

Eli Lilly said federal regulators have approved of a single-injection, once-monthly maintenance regimen in the U.S. for its ulcerative colitis treatment Omvoh.

BDF-GESTION sold 4,149 shares of Eli Lilly ( LLY 0.58%) stock during the quarter. The estimated transaction value was $3.09 million, using the average unadjusted closing price for the quarter. After ...

Marcus Partners secured roughly 236K SF of leases across its Greater Boston logistics portfolio. The firm completed a full ...